Eton Pharmaceuticals Inc (ETON) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.64 is considered Undervalued compared with the five-year average of 30.48. The fair price of Eton Pharmaceuticals Inc (ETON) is between 26.97 to 35.57 according to relative valuation method. Compared to the current price of 18.15 USD , Eton Pharmaceuticals Inc By Undervalued By 32.7%.

Relative Value

Fair Zone

26.97-35.57

Current Price：18.15

32.7%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Eton Pharmaceuticals Inc (ETON) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Eton Pharmaceuticals Inc (ETON) has a current Price-to-Book (P/B) ratio of 18.86. Compared to its 3-year average P/B ratio of 12.31, the current P/B ratio is approximately 53.19% higher. Relative to its 5-year average P/B ratio of 9.94, the current P/B ratio is about 89.61% higher. Eton Pharmaceuticals Inc (ETON) has a Forward Free Cash Flow (FCF) yield of approximately 4.82%. Compared to its 3-year average FCF yield of 3.71%, the current FCF yield is approximately 29.92% lower. Relative to its 5-year average FCF yield of -0.21%, the current FCF yield is about -2347.21% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for ETON competitors is 22.42, providing a benchmark for relative valuation. Eton Pharmaceuticals Inc Corp (ETON.O) exhibits a P/S ratio of 4.64, which is -79.3% above the industry average. Given its robust revenue growth of 117.54%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of ETON increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of ETON in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is ETON currently overvalued or undervalued?

Eton Pharmaceuticals Inc (ETON) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.64 is considered Undervalued compared with the five-year average of 30.48. The fair price of Eton Pharmaceuticals Inc (ETON) is between 26.97 to 35.57 according to relative valuation method. Compared to the current price of 18.15 USD, Eton Pharmaceuticals Inc is Undervalued By 32.70%.

What is Eton Pharmaceuticals Inc (ETON) fair value?

ETON's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Eton Pharmaceuticals Inc (ETON) is between 26.97 to 35.57 according to relative valuation method.

How does ETON's valuation metrics compare to the industry average?

The average P/S ratio for ETON's competitors is 22.42, providing a benchmark for relative valuation. Eton Pharmaceuticals Inc Corp (ETON) exhibits a P/S ratio of 4.64, which is -79.30% above the industry average. Given its robust revenue growth of 117.54%, this premium appears sustainable.

What is the current P/B ratio for Eton Pharmaceuticals Inc (ETON) as of Mar 03 2026?

As of Mar 03 2026, Eton Pharmaceuticals Inc (ETON) has a P/B ratio of 18.86. This indicates that the market values ETON at 18.86 times its book value.

What is the current FCF Yield for Eton Pharmaceuticals Inc (ETON) as of Mar 03 2026?

As of Mar 03 2026, Eton Pharmaceuticals Inc (ETON) has a FCF Yield of 4.82%. This means that for every dollar of Eton Pharmaceuticals Inc's market capitalization, the company generates 4.82 cents in free cash flow.

What is the current Forward P/E ratio for Eton Pharmaceuticals Inc (ETON) as of Mar 03 2026?

As of Mar 03 2026, Eton Pharmaceuticals Inc (ETON) has a Forward P/E ratio of 29.39. This means the market is willing to pay $29.39 for every dollar of Eton Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Eton Pharmaceuticals Inc (ETON) as of Mar 03 2026?

As of Mar 03 2026, Eton Pharmaceuticals Inc (ETON) has a Forward P/S ratio of 4.64. This means the market is valuing ETON at $4.64 for every dollar of expected revenue over the next 12 months.

ETON Valuation